Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
about
Primary-care-based episodes of care and their costs in a three-month follow-up in FinlandCost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.Administration costs of intravenous biologic drugs for rheumatoid arthritis.Cost-effectiveness of rituximab in follicular lymphoma.Overview of parametric survival analysis for health-economic applications.Are high drug prices for hematologic malignancies justified? A critical analysis.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)
P2860
Q36572089-FAAF1A81-C1BF-450B-B02E-C5AC497E98A5Q37184310-5031FA91-F4B2-42C3-A01A-A6CDFDBFDB77Q37301258-458581C7-22B1-488D-8ABB-6C845C401FC3Q38058840-2EFEBC6A-B8D6-45EB-BCDC-D765AC2292C0Q38106867-CE50A97E-D991-402A-A80A-5A3364B34502Q38535347-F5EB3B03-1183-4C22-BB6F-87398691D3E6Q38610648-5545FB17-70CD-49C7-AE67-26C1680BE9E0Q39885004-8A11924F-6479-4847-B555-955DFA8BB6CFQ44908024-47787955-78D3-4630-9D18-2E8D94076B61Q46675870-4648BB04-F418-4E00-8874-D1AA25B499B7Q47108715-11423B29-FC2C-4556-BA07-41CF36DA6169Q58919297-D095C465-B7AE-4A90-871E-72653CE2AAC8
P2860
Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@ast
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@en
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@nl
type
label
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@ast
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@en
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@nl
prefLabel
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@ast
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@en
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Treatment of follicular non-Ho ...... n based on a 5-year follow-up.
@en
P2093
E J O Soini
J A Martikainen
T Nousiainen
P2860
P304
P356
10.1093/ANNONC/MDQ582
P577
2010-12-06T00:00:00Z